Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brand-Boosting Schiff Nutrition Sees Upside In Top-Selling Supplements

This article was originally published in The Tan Sheet

Executive Summary

Schiff Nutrition CEO Tarang Amin, a veteran of managing brands for Clorox and P&G, sees additional upside in top-selling brands such as MegaRed and Move Free. The firm also is de-emphasizing its struggling private label business.

You may also be interested in...



NBTY Moves On From U.K. Health Food Retail Misadventure

Less than four years after acquiring U.K. chain Julian Graves as a platform for European growth, NBTY absorbs a $20 mil. charge to get rid of the subsidiary, which had “continuing operating losses.” NBTY plans to refocus resources on Holland & Barrett and its other European supplement retailers.

NBTY Moves On From U.K. Health Food Retail Misadventure

Less than four years after acquiring U.K. chain Julian Graves as a platform for European growth, NBTY absorbs a $20 mil. charge to get rid of the subsidiary, which had “continuing operating losses.” NBTY plans to refocus resources on Holland & Barrett and its other European supplement retailers.

Schiff Nutrition Enlists Airborne For Sortie Into Immune Support

The $150 million price represents more than twice Airborne’s approximately $70 million in annual net revenues for supplements marketed to strengthen immune support. The acquisition from GF Capital follows Pfizer’s recent foray into the immune support space by buying the maker of Emergen-C products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel